Evidence map›Paper›PMID 36357544›Full record

ArticleScientific reports2022

Reduction of glutamatergic activity through cholinergic dysfunction in the hippocampus of hippocampal cholinergic neurostimulating peptide precursor protein knockout mice.

Kengo Suzuki, Yoshiaki Ohi, Toyohiro Sato, Yo Tsuda, Yuta Madokoro, Masayuki Mizuno, Kenichi Adachi, Yuto Uchida, Akira Haji, Kosei Ojika and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in AppAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kengo SuzukiDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Yoshiaki OhiLaboratory of Neuropharmacology, School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto, Chikusa-Ku, Nagoya, 464-8650, Japan.
Toyohiro SatoDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Yo TsudaDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Yuta MadokoroDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Masayuki MizunoDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Kenichi AdachiDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Yuto UchidaDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Akira HajiLaboratory of Neuropharmacology, School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto, Chikusa-Ku, Nagoya, 464-8650, Japan.
Kosei OjikaDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan.
Noriyuki MatsukawaDepartment of Neurology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-Ku, Nagoya, 467-8602, Japan. norim@med.nagoya-cu.ac.jp.
Nagoya City University · JPAichi Gakuin University · JP

Funding

KAKENHI 19K16922KAKENHI 20K07891
6 · The paper itself

Abstract

Cholinergic activation can enhance glutamatergic activity in the hippocampus under pathologic conditions, such as Alzheimer's disease. The aim of the present study was to elucidate the relationship between glutamatergic neural functional decline and cholinergic neural dysfunction in the hippocampus. We report the importance of hippocampal cholinergic neurostimulating peptide (HCNP) in inducing acetylcholine synthesis in the medial septal nucleus. Here, we demonstrate that HCNP-precursor protein (pp) knockout (KO) mice electrophysiologically presented with glutamatergic dysfunction in the hippocampus with age. The impairment of cholinergic function via a decrease in vesicular acetylcholine transporter in the pre-synapse with reactive upregulation of the muscarinic M1 receptor may be partly involved in glutamatergic dysfunction in the hippocampus of HCNP-pp KO mice. The results, in combination with our previous reports that show the reduction of hippocampal theta power through a decrease of a region-specific choline acetyltransferase in the stratum oriens of CA1 and the decrease of acetylcholine concentration in the hippocampus, may indicate the defined cholinergic dysfunction in HCNP-pp KO mice. This may also support that HCNP-pp KO mice are appropriate genetic models for cholinergic functional impairment in septo-hippocampal interactions. Therefore, according to the cholinergic hypothesis, the model mice might are potential partial pathological animal models for Alzheimer's disease.

Indexed as

Alzheimer DiseasePhosphatidylethanolamine Binding ProteinAcetylcholineAnimalsCholinergic AgentsHippocampusMiceMice, KnockoutAcetylcholineCholinergic AgentsPhosphatidylethanolamine Binding Protein

Identifiers

PMID36357544
PMCPMC9649636
OpenAlexW4308888210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.